Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: influenza A/B virus inhibitors - Cocrystal Phama

Next Previous
Drug Profile

Research programme: influenza A/B virus inhibitors - Cocrystal Phama

Alternative Names: Influenza A/B inhibitors - Cocrystal Phama/Merck

Latest Information Update: 04 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cocrystal Pharma Inc
  • Class Antivirals; Small molecules
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Influenza A virus infections; Influenza B virus infections

Most Recent Events

  • 27 Oct 2025 Cocrystal Pharma receives SBIR grant from National Institute of Allergy and Infectious Diseases (NIAID).to support the Influenza A and B virus infection program
  • 29 Feb 2024 Preclinical development is ongoing USA in Influenza A virus infections and Influenza B virus infections (Cocrystal pharma pipeline, February 2024)
  • 15 Dec 2023 Cocrystal Pharma terminates licensing and collaboration agreement with Merck for the development and commercialisation of Influenza A/B antiviral agents

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top